Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named
SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards
the end of 2019. Large-scale spread within China and internationally led the World
Health Organization to declare a Public Health Emergency of International Concern
on 30th January 2020. The clinical manifestations of COVID-19 virus infection
include asymptomatic infection, mild upper respiratory symptoms, severe viral
pneumonia with respiratory failure, and even death. There are no antivirals of
proven clinical efficacy in coronavirus infections. Remdesivir (GS-5734), a
nucleoside analogue, has inhibitory effects on animal and human highly pathogenic
coronaviruses, including MERS-CoV and SARS-CoV, in in vitro and in vivo
experiments. It is also inhibitory against the COVID-19 virus in vitro. The aim of
this study is to assess the efficacy and safety of remdesivir in adult patients with
severe COVID-19.

제 1편 코로나바이러스 정의
1. 코로나바이러스감염증-19(Covid-19) 정보 7
2. 코로나바이러스 분류 및 특성 9
3. 코로나바이러스 전자현미경 형태 11
4. 코로나바이러스 구조 (Covid-19 Organization) 13
5. 코로나19: 환경에 지속적인 영향을 미칠까? 19
6. 치료법(Therapeutical Method) 22

제 2편 연구논문
Evaluation of the efficacy and safety of intravenous remdesivir in
adult patients with severe COVID-19: study protocol for a
phase 3 randomized, double-blind, placebo-controlled, multicentre trial

1. Introduction 23
2. Methods: participants, interventions, and outcomes 25
3. Interventions 25
4. Data collection and management 27
5. Statistical methods 29
6. Discussion 31
7. References 33